Patents by Inventor Liewei Wang
Liewei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11908121Abstract: Provided are a method and a device for real-time monitoring of tunnel deformation. The monitoring method includes: S1, erecting a plurality of structured light sources in an unstable area to be monitored of a tunnel structure, and erecting a monitoring terminal in a relatively stable region of the tunnel structure, where the monitoring terminal may communicate with the plurality of structured light sources; S2, observing all structured lights in the unstable area of the tunnel structure and obtaining structured light curves in real time by the monitoring terminal; S3, analyzing imaging changes of the structured lights, detecting deformation degrees and offset distances of the tunnel in real time, and monitoring the diseases such as settlement, convergence of a single-section of the tunnel and integral settlement of a multi-section of the tunnel by the data processing unit.Type: GrantFiled: August 8, 2023Date of Patent: February 20, 2024Assignee: NANJING PIONEER AWARENESS INFORMATION TECHNOLOGY CO., LTDInventors: Zhengying Shi, Weike Xin, Shu Li, Liewei Wang, Jie Lian, Youqun Huang, Haidong Lu, Yang Li, Peiyao Li, Guoqiang Wu, Baoqian Xia
-
Patent number: 11869633Abstract: The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention.Type: GrantFiled: December 14, 2018Date of Patent: January 9, 2024Assignee: The Board of Trustees of the University of IllinoisInventors: Ravishankar Krishnan Iyer, Arjun Prasanna Athreya, Richard Merle Weinshilboum, Liewei Wang, William Victor Bobo, Mark Andrew Frye
-
Patent number: 11865163Abstract: This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.Type: GrantFiled: September 15, 2017Date of Patent: January 9, 2024Assignee: Mayo Foundation for Medical Education and ResearchInventors: William S. Brimijoin, Liewei Wang, Yang Gao, Ping Chen, Liyi Geng, Jia Yu, Judy C. Boughey, Matthew P. Goetz
-
Publication number: 20230386006Abstract: Provided are a method and a device for real-time monitoring of tunnel deformation. The monitoring method includes: S1, erecting a plurality of structured light sources in an unstable area to be monitored of a tunnel structure, and erecting a monitoring terminal in a relatively stable region of the tunnel structure, where the monitoring terminal may communicate with the plurality of structured light sources; S2, observing all structured lights in the unstable area of the tunnel structure and obtaining structured light curves in real time by the monitoring terminal; S3, analyzing imaging changes of the structured lights, detecting deformation degrees and offset distances of the tunnel in real time, and monitoring the diseases such as settlement, convergence of a single-section of the tunnel and integral settlement of a multi-section of the tunnel by the data processing unit.Type: ApplicationFiled: August 8, 2023Publication date: November 30, 2023Inventors: Zhengying SHI, Weike XIN, Shu LI, Liewei WANG, Jie LIAN, Youqun HUANG, Haidong LU, Yang LI, Peiyao LI, Guoqiang WU, Baoqian XIA
-
Patent number: 11497729Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340+ cancer cells such as HER2+ cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2+ breast cancer that was refractory to trastuzumab alone treatment) are provided.Type: GrantFiled: July 7, 2017Date of Patent: November 15, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: Liewei Wang, Matthew P. Goetz, Judy C. Boughey, Jia Yu, Bo Qin
-
Patent number: 11122997Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.Type: GrantFiled: April 15, 2016Date of Patent: September 21, 2021Assignees: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke UniversityInventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
-
Publication number: 20210283101Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for using an inhibitor of USP7 polypeptide to increase the sensitivity of cancer cells (e.g., CD340+ cancer cells such as HER2+ cancer cells) to treatment with an inhibitor of a CD340 polypeptide (e.g., an inhibitor of a HER2 polypeptide) are provided. Methods and materials for using USP7 polypeptide inhibitors in combination with CD340 polypeptide inhibitors to treat cancer (e.g., HER2+ breast cancer that was refractory to trastuzumab alone treatment) are provided.Type: ApplicationFiled: July 7, 2017Publication date: September 16, 2021Applicant: Mayo Foundation for Medical Education and ResearchInventors: Liewei Wang, Matthew P. Goetz, Judy C. Boughey, Jia Yu, Bo Qin
-
Patent number: 10815534Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.Type: GrantFiled: August 22, 2017Date of Patent: October 27, 2020Assignee: Mayo Foundation for Medical Education and ResearchInventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
-
Publication number: 20190255154Abstract: This document provides methods and materials for using butyrylcholinesterases (BChE) to treat cancer (e.g., triple negative breast cancer or prostate cancer). For example, methods and materials for using nucleic acid vectors (e.g., viral vectors) to express BChE polypeptides under conditions that reduce the number of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) and/or reduce the growth rate of cancer cells (e.g., triple negative breast cancer cells or prostate cancer cells) within a mammal (e.g., a human) are provided.Type: ApplicationFiled: September 15, 2017Publication date: August 22, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: William S. Brimijoin, Liewei Wang, Yang Gao, Ping Chen, Liyi Geng, Jia Yu, Judy C. Boughey, Matthew P. Goetz
-
Publication number: 20190194761Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.Type: ApplicationFiled: August 22, 2017Publication date: June 27, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
-
Publication number: 20190189247Abstract: The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention.Type: ApplicationFiled: December 14, 2018Publication date: June 20, 2019Applicants: The Board of Trustees of the University of Illinois, Mayo Foundation for Medical Education and ResearchInventors: Ravishankar K. Iyer, Arjun Prasanna Athreya, Richard Merle Weinshilboum, Liewei Wang, William Victor Bobo, Mark Andrew Frye
-
Patent number: 10220016Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.Type: GrantFiled: February 17, 2016Date of Patent: March 5, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
-
Publication number: 20180098722Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.Type: ApplicationFiled: April 15, 2016Publication date: April 12, 2018Applicants: Mayo Foundation for Medical Education and Research, Ixcela Inc., Duke UniversityInventors: Balmiki Ray, Liewei Wang, Joanna Biernacka, Mark Frye, Richard M. Weinshilboum, Michiaki Kubo, Taisei Mushiroda, Wayne R. Matson, Rima Kaddurah-Daouk
-
Publication number: 20180021295Abstract: This document provides methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) is likely to respond to chemotherapy (e.g., a taxane therapy) based at least in part on the presence of a variant in the mammal's polycystic kidney disease gene 1 (PKD1) are provided. In addition, methods and materials involved in treating mammals having cancer (e.g., breast cancer) by administering an inhibitor of ubiquitin specific peptidase 2 (USP2) polypeptide activity (e.g., NSC-632839, a 2-cyano-pyrimidine, or a 2-cyano-triazine) in combination with another chemotherapeutic agent such as a taxane therapy are provided.Type: ApplicationFiled: February 17, 2016Publication date: January 25, 2018Applicant: Mayo Foundation for Medical Education and ResearchInventors: Matthew P. Goetz, Judy C. Boughey, Liewei Wang, Krishna R. Kalari, Richard M. Weinshilboum, Vera J. Suman
-
Publication number: 20120021920Abstract: Materials and methods related to using biomarkers for prediction of response to radiation therapy.Type: ApplicationFiled: April 1, 2010Publication date: January 26, 2012Applicant: Mayo Foundation for Medical Education and ResearchInventors: Liewei Wang, Richard M. Weinshilboum, Krishna Kalari, Brooke L. Fridley, Yu Xin Qin
-
Patent number: 7858306Abstract: Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.Type: GrantFiled: July 7, 2006Date of Patent: December 28, 2010Assignee: Mayo Foundation for Medical Education and ResearchInventors: Richard M. Weinshilboum, Linda L. Pelleymounter, Eric D. Wieben, Oreste Salavaggione, Liewei Wang
-
Publication number: 20100311606Abstract: Materials and methods for evaluating cellular response to therapeutic agents.Type: ApplicationFiled: May 7, 2008Publication date: December 9, 2010Inventors: Liewei Wang, Richard M. Weinshilboum, Liang Li, Brooke L. Fridley, Krishna Kalari, Daniel Schaid, Matthew M. Ames
-
Patent number: 7485711Abstract: Isolated CYP19A1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as CYP19A1 allozymes. Methods for determining the aromatase status of an individual also are provided, as are methods for determining if a subject is predisposed to certain clinical conditions.Type: GrantFiled: August 16, 2005Date of Patent: February 3, 2009Assignee: Mayo Foundation for Medical Education and ResearchInventors: Richard M. Weinshilboum, Eric O. Wieben, Oreste Salavaggione, Araba A. Adjei, Linda Pelleymounter, Josefa Coronel, Liewei Wang, Bruce Eckloff, Daniel Schaid, Cynthia X. Ma
-
Publication number: 20090023136Abstract: Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided.Type: ApplicationFiled: July 7, 2006Publication date: January 22, 2009Inventors: Richard M. Weinshilboum, Linda L. Pelleymounter, Eric D. Wieben, Oreste Salavaggione, Liewei Wang
-
Publication number: 20070037177Abstract: Isolated CYP19A1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as well as CYP19A1 allozymes. Methods for determining the aromatase status of an individual also are provided, as are methods for determining if a subject is predisposed to certain clinical conditions.Type: ApplicationFiled: August 16, 2005Publication date: February 15, 2007Inventors: Richard Weinshilboum, Eric Wieben, Oreste Salavaggione, Araba Adjei, Linda Pelleymounter, Josefa Coronel, Liewei Wang, Bruce Eckloff, Daniel Schaid, Cynthia Ma